This observational study, sponsored by Fondazione IRCCS Ca' Granda, aims to elucidate the behavior of ECFCs in patients with von Willebrand disease (VWD) and acquired von Willebrand syndrome (AVWS) compared to healthy controls. The findings may provide insights into the cellular and molecular alterations associated with VWD, potentially leading to novel therapeutic strategies. The market for VWD treatments is significant, with a growing demand for innovative therapies addressing the underlying mechanisms of bleeding disorders. Competitive implications include the potential for new entrants focusing on gene therapy and cellular therapies targeting VWF deficiencies. Diligence considerations should include the study's design, patient recruitment, and the robustness of the data collection methods.